2025 annual financial data

Inhibikase Therapeutics 2025 Financial results

Direct answer

Revenue was 0 USD.

Operating income was -51.97M USD and net income was -48.26M USD.
Operating cash flow was -27.79M USD.

Get free Inhibikase Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
0 USD
Operating income
-51.97M USD
Net income
-48.26M USD
Operating cash flow
-27.79M USD